Rheumatology
-
Randomized Controlled Trial
Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity.
To evaluate the relationship between radiographic progression and disease activity in subjects with PsA treated with adalimumab (ADA) or placebo (PBO) and the impact of concomitant MTX. ⋯ Among subjects with PsA treated with ADA, there was evidence of a 'disconnect' between disease activity and radiographic progression: inhibition of radiographic progression was greater than expected based on control of clinical disease activity alone. MTX had no added effect.